source
- RevMed's Rasonque shows strong first-line response and survival benefit in early pancreatic cancer dataRevMed reported early-stage results from its open‑label Phase 1/2 RMC‑GI‑102 trial, presented at the EORTC‑N conference, evaluating Rasonque combined with chemotherapy in patients with first‑line m…
- Merck's sac-TMT antibody-drug conjugate achieves positive Phase 3 results in gastric cancerMerck announced that its experimental antibody-drug conjugate sacituzumab-TMT (sac-TMT) met primary endpoints in a pivotal Phase 3 trial in patients with gastric cancer. The trial outcome represen…Endpoints · 1h agoPositive readoutPositive